{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:06:43Z","timestamp":1778864803734,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["bmrp148"],"award-info":[{"award-number":["bmrp148"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Chronic hepatitis C virus (HCV), which is a concern in many countries, is the leading cause of liver cancer around the world. Since Taiwan launched its national health insurance system in 1995, it has managed to extend health coverage to 99% of the Taiwanese population, providing free but limited antiviral treatment each year since 2017. However, many people in rural areas are unaware that they have chronic HCV; nor do they realize that new drugs with high cure rates could drastically reduce their health burden. The aim of this study is to explore the implementation facilitators of and barriers to inviting potentially infected patients in rural areas to be transferred for HCV ribonucleic acid (RNA) confirmation and new drug treatment.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A descriptive and prospective study design with an interdisciplinary collaboration approach was implemented. After five elements of referral were developed, telephone counseling was conducted between August 2018 and May 2019 in Yunlin, Taiwan. The elements of referral developed by the research team were: (1) forming and coordinating physicians\u2019 schedules, (2) recruiting and training volunteers, (3) training the nursing staff, (4) raising funds or resources, and (5) connecting with village leaders. Thereafter, we collaborated with two district health centers, a private local hospital, and health clinics. Based on the medical records provided by these agencies, community adults that were HCV antibody (anti-HCV) positive were invited to join the program.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Of the 1795 adults who were serum anti-HCV positive, 1149 (64%) accepted transfer to a qualified hospital; of these, 623 (54.2%) had an HCV infection. 552 (88.6%) of those infected started receiving direct-acting antivirals (DAAs) treatment. The top four barriers to accepting transfer were: (1) they perceived themselves to be healthy (<jats:italic>n<\/jats:italic>\u00a0=\u200998, 32.3%); (2) mistrust of treatment\/healthcare (<jats:italic>n<\/jats:italic>\u00a0=\u200960, 20.2%); (3) limited transportation to the hospital (<jats:italic>n<\/jats:italic>\u2009=\u200952, 17.5%); and (4) work conflict (<jats:italic>n<\/jats:italic>\u2009=\u200930, 10.1%).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>An interdisciplinary collaboration approach significantly contributed to the invitation of CHC patients, as well as their acceptance of HCV RNA confirmation and free DAAs treatment. Using anti-HCV data from previous medical records for case-finding and collaborating with a hospital and health clinics proved to be an efficient strategy.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12879-020-05435-3","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T13:03:57Z","timestamp":1602075837000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Challenges of transferring rural adults with chronic HCV infection for further HCV RNA confirmation and free DAAs treatment: a success story of the interdisciplinary collaboration approach"],"prefix":"10.1186","volume":"20","author":[{"given":"Wei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Te-Sheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Zhi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Hwa","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8980-1300","authenticated-orcid":false,"given":"Mei-Yen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,7]]},"reference":[{"key":"5435_CR1","unstructured":"World Health Organization, WHO. Fact sheet: Hepatitis C. http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c (accessed 30 August 2019)."},{"key":"5435_CR2","unstructured":"Centers for Disease Control and Prevention, CDC. Viral hepatitis. https:\/\/www.cdc.gov\/hepatitis\/ (accessed 1 August 2019)."},{"issue":"10","key":"5435_CR3","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1002\/jmv.25533","volume":"91","author":"T Tada","year":"2019","unstructured":"Tada T, Toyoda H, Yasuda S, Miyake N, Kumada T, Kurisu A, et al. Natural history of liver-related disease in patients with chronic hepatitis C virus infection: an analysis using a Markov chain model. J Med Virol. 2019;91(10):1837\u201344.","journal-title":"J Med Virol"},{"key":"5435_CR4","doi-asserted-by":"crossref","unstructured":"Lin C, Clark R, Tu P, Tu R, Hsu YJ, Nien HC. The disconnect in hepatitis screening: participation rates, awareness of infection status, and treatment-seeking behavior. J Glob Health. 2019;9(1):010426.","DOI":"10.7189\/jogh.09.010426"},{"key":"5435_CR5","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.cmi.2016.07.035","volume":"22","author":"S Lanini","year":"2016","unstructured":"Lanini S, Easterbrook PJ, Zumla A, Ippolito G. Hepatitis C: global epidemiology and strategies for control. Clin Microbiol Infect. 2016;22:833\u20138.","journal-title":"Clin Microbiol Infect"},{"key":"5435_CR6","unstructured":"National Health Insurance, NHI. Hepatitis C full oral new drug health insurance payment implementation plan. https:\/\/www.nhi.gov.tw\/Content_List.aspx?n=A4EFF6CD1C4891CA&topn=3FC7D09599D25979 (accessed 10 August 2019)."},{"issue":"8","key":"5435_CR7","doi-asserted-by":"publisher","first-page":"e186371","DOI":"10.1001\/jamanetworkopen.2018.6371","volume":"1","author":"ES Rosenberg","year":"2018","unstructured":"Rosenberg ES, Rosenthal EM, Hall EW, Barker L, Hofmeister MG, Sullivan PS, et al. Prevalence of hepatitis C virus infection in US states and the District of Columbia, 2013 to 2016. JAMA Netw Open. 2018;1(8):e186371.","journal-title":"JAMA Netw Open"},{"key":"5435_CR8","unstructured":"Taiwan Medical Association, TMA. Hepatitis C epidemiology and prevention strategy. http:\/\/www.fma.org.tw\/2016\/I-1-3.html (accessed 20 August 2019)."},{"key":"5435_CR9","doi-asserted-by":"crossref","unstructured":"Domont\u00a0F,\u00a0Cacoub\u00a0P. Chronic hepatitis C virus infection, a new cardiovascular risk factor? Liver Int. 2016;36(5):621\u20137.","DOI":"10.1111\/liv.13064"},{"key":"5435_CR10","doi-asserted-by":"crossref","unstructured":"Yoo ER,\u00a0Perumpail RB,\u00a0Cholankeril G,\u00a0Jayasekera CR,\u00a0Ahmed A. Expanding treatment access for chronic hepatitis C with task-shifting in the era of direct-acting antivirals. J. Clin. Transl. Hepatol.\u00a02017;5(2):130\u20133.","DOI":"10.14218\/JCTH.2016.00059"},{"key":"5435_CR11","doi-asserted-by":"crossref","unstructured":"Younossi ZM,\u00a0Park H,\u00a0Dieterich D,\u00a0Saab S,\u00a0Ahmed A,\u00a0Gordon SC. The value of cure associated with treating treatment-na\u00efve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society? Liver Int.\u00a02017;37(5):662\u20138.","DOI":"10.1111\/liv.13298"},{"key":"5435_CR12","doi-asserted-by":"crossref","unstructured":"Chen DS. Taiwan commits to eliminating hepatitis C in 2025. Lancet Infect. Dis. 2019;19(5):466.","DOI":"10.1016\/S1473-3099(19)30170-7"},{"key":"5435_CR13","doi-asserted-by":"crossref","unstructured":"Saab S,\u00a0Le L,\u00a0Saggi S,\u00a0Sundaram V,\u00a0Tong MJ. Toward the elimination of hepatitis C in the United States. Hepatology. 2018;67(6):2449\u201359.","DOI":"10.1002\/hep.29685"},{"key":"5435_CR14","doi-asserted-by":"crossref","unstructured":"Ward JW,\u00a0Mermin JH. Simple, effective, but out of reach? Public health implications of\u00a0HCV\u00a0drugs. N. Engl J Med 2015;73(27):2678\u201380.","DOI":"10.1056\/NEJMe1513245"},{"key":"5435_CR15","doi-asserted-by":"crossref","unstructured":"Castro R, Crathorne L, Perazzo H, Silva J, Cooper C, Varley-Campbell J, et al. Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses. BMC Med Res Methodol. 2018;18(1):53.","DOI":"10.1186\/s12874-018-0515-9"},{"key":"5435_CR16","doi-asserted-by":"crossref","unstructured":"Treloar C, Rance J, Backmund M. Understanding barriers to hepatitis C virus care and stigmatization from a social perspective.\u00a0Clin Infect Dis.\u00a02013;57(suppl2):S51\u20135.","DOI":"10.1093\/cid\/cit263"},{"key":"5435_CR17","doi-asserted-by":"crossref","unstructured":"Burki T. Eliminating hepatitis C. Lancet Infect Dis. 2019;19:246\u20137.","DOI":"10.1016\/S1473-3099(19)30073-8"},{"key":"5435_CR18","doi-asserted-by":"crossref","unstructured":"Pourmarzi D,\u00a0Smirnov A,\u00a0Hepworth J,\u00a0Rahman T,\u00a0FitzGerald G, Hall L.\u00a0 Elements of community-based models for treating hepatitis C virus in supporting\u00a0HCV elimination in Australia: A Delphi study. Int J Health Plann Manage. 2019;34(2):e1247\u201356.","DOI":"10.1002\/hpm.2770"},{"key":"5435_CR19","doi-asserted-by":"crossref","unstructured":"White L,\u00a0Azzam A,\u00a0Burrage L,\u00a0Orme C,\u00a0Kay B,\u00a0Higgins S,O'Beirne J. Facilitating treatment of\u00a0HCV\u00a0in primary care in regional Australia: closing the access gap. Frontline Gastroenterol. 2019;10(3):210\u20136.","DOI":"10.1136\/flgastro-2018-101049"},{"key":"5435_CR20","doi-asserted-by":"crossref","unstructured":"Cheng PN, Chiu YC, Chiu HC, Chien SC. The characteristics of residents with unawareness of hepatitis C virus infection in community. PloS One. 2018;13(2):e0193251.","DOI":"10.1371\/journal.pone.0193251"},{"key":"5435_CR21","doi-asserted-by":"crossref","unstructured":"Butt G. Stigma in the context of hepatitis C: concept analysis. J Adv Nurs. 2008;62(6):712\u201324.","DOI":"10.1111\/j.1365-2648.2008.04641.x"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05435-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-020-05435-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05435-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T01:53:56Z","timestamp":1633571636000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05435-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,7]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5435"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05435-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,7]]},"assertion":[{"value":"12 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the subjects provided written informed consent before participating in the study, and the study design was approved by the Chang Gung Memorial Hospital\u2019s Institutional Review Board (No: 201701919B0).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"737"}}